About us
Services & Solutions
Chemistry DMPK Discovery Biology Oncology Pharmacology Biologics
Medicinal Chemistry Computational Chemistry Synthetic Chemistry Analytical Chemistry Scale Up Chemistry
In Vivo PK and TK In Vitro ADME Bioanalytical Service Exploratory Toxicity In Rodents, Dogs and Monkeys Large Molecules Capabilities Bioanalytical Instruments
Biochemical Assays Cellular Assays Protein Science Assay Technologies Biophysics SPR Safety Pharmacology Screening Services Key Instruments
PDX CDX Orthotopic Models Syngeneic Models Humanized Mouse Models CAR-T and CAR-NK Mouse Models In Vitro Assays
Immunology Inflammation Metabolic NASH Respiratory Neuroscience
Systematic Antibody Discovery Service
Process R&D Scale Up Synthesis DS Manufacturing
Flow Chemistry Sugar Chemistry Peptide Chemistry Preparative Purification Capacity Process Safety Assessment
Synthetic and Scale Up Chemistry Parallel Synthesis
Flow Chemistry Pilot plant QA EHS
Pre-Formulation Formulation, Analytical and Process Development Drug Product Manufacturing
Bioavailability Enhancement Modified Release
Commercial Manufacturing
Platforms
News & Resources
Careers
Contact us
CN EN
×
news
Company News Events Insights Webinars
BioDuro-Sundia Announces New CEO
SAN DIEGO and SHANGHAI, February 09, 2021 – BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today the appointment of Haiju
February 09, 2021
BioDuro-Sundia received the “2020 EXCELLENT Team Service” award from Lynk Pharmaceuticals
SAN DIEGO and SHANGHAI, January 18, 2021 – BioDuro-Sundia received the “2020 EXCELLENT Team Service” award from Lynk Pharmaceuticals, as recognition of the efforts and contributions made by the BioDuro-
January 18, 2021
Congratulations to DartsBio Pharmaceutical for Analgesic DS002 Injection Approved for Clinical Trial by NMPA
​Shanghai, December 25, 2020 – Congratulations to DartsBio Pharmaceutical (Guangdong) Co., Ltd. (hereinafter referred to as “DartsBio”) for their self-developed human recombinant monoclonal antibody DS002  targeting NGF has be
December 25, 2020
Congratulations To GenFleet Therapeutics For Selective CDK9 Inhibitor GFH009 Injection Approved For Clinical Trial by NMPA
Shanghai, December 21,2020 – Congratulations to GenFleet Therapeutics Inc. for their selective CDK9 inhibitor GFH009 Injection have been approved by the CDE (Center for Drug Evaluation), NMPA for clinical trials. It has received
December 21, 2020
BioDuro & Silexon Form Strategic Collaboration to Develop New Anti-Cancer Drugs
SAN DIEGO and SHANGHAI, December 03, 2020 – BioDuro LLC, a leading global life sciences contract research, development and manufacturing organization (CRDMO), and Silexon, a cutting-edge AI-empower
December 03, 2020
Total 78 12345678...1516
Subscribe to BioDuro-Sundia
Receive our newsletter and information on upcoming events
Your trusted partner from drug discovery and
development to commercialization

Home

About us

Services & Solutions

Platforms

News & Resources

Careers

Contact us

Explore

Discovery

Drug Substance

Drug Product

© 2023 BioDuro-Sundia. All rights reserved
Terms of Use Privacy Policy
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all